ArticleJournal of ultrasonography2025
Ultrasonography: an aid in molecular subtyping of breast carcinoma.
Article in Journal of ultrasonography, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The recognition of molecular subtypes of breast cancer has initiated a new regimen of targeted therapy. Early diagnosis is a key step in improving survival. Therefore, a cost-effective and widely available imaging tool is needed for the timely detection and prediction of the molecular profile of breast cancer. Aim: To study the predictive value of ultrasonographic features in identifying the estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 neu (HER2/neu) expression status, and molecular subtypes of breast cancer. Material and methods: We conducted a study on 51 histopathologically proven invasive breast carcinoma cases over a period of one and a half years. The patients underwent ultrasonography followed by tissue biopsy. Sonographic parameters were assessed based on BI-RADS imaging features. The molecular subtypes of breast cancer were grouped into four subtypes based on the St. Gallen International Expert Consensus Panel. The predictive value of ultrasonographic features was then studied in relation to the hormone receptor status and molecular subtypes of breast cancer. Results: A significant association between posterior acoustic features and molecular subtypes was seen. Posterior acoustic shadowing was associated with progesterone receptor status with an odds ratio (OR) of 36.58, confidence interval (CI) of 5.527-866.1, and Conclusion: Certain sonographic features are associated with the estrogen/progesterone receptor hormone receptor status and molecular subtypes of breast cancer. With validation of this association, ultrasound may serve as a basic imaging modality for predicting molecular subtypes of breast cancer even in remote areas, where immunohistochemistry hormone receptor and HER2 testing are not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.